Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lomustine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lomustine | Belustine | CCNU |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03970447 | Phase II | Lomustine Regorafenib Temozolomide | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | DEU | CHE | CAN | AUS | 0 |
NCT01860638 | Phase III | Bevacizumab Lomustine | A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma | Completed | TUR | SWE | ROU | LVA | ITA | HRV | GRC | GBR | FRA | EST | ESP | CAN | BGR | AUT | 1 |
NCT02414165 | Phase II | Bevacizumab Lomustine Toca FC + Vocimagene amiretrorepvec Temozolomide | P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) | Terminated | USA | ISR | CAN | 1 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Recruiting | USA | NLD | ITA | CHE | 0 |
NCT04765098 | Phase II | Tamoxifen Lomustine | Tamoxifen Versus Lomustine After First Recurrence in GBM Patients | Recruiting | CAN | 0 |
NCT01989052 | Phase Ib/II | Lomustine Carboxyamidotriazole Orotate | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Terminated | USA | 0 |
NCT04573192 | Phase Ib/II | Lomustine + Onfekafusp alfa Lomustine | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR) | Recruiting | ITA | FRA | DEU | CHE | 0 |
NCT06325683 | Phase II | Nivolumab + Relatlimab Lomustine | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT02343406 | Phase II | Lomustine Depatuxizumab mafodotin Temozolomide | ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma | Completed | USA | POL | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
NCT04421378 | Phase Ib/II | Lomustine + Selinexor Lomustine Selinexor + Temozolomide Temozolomide Selinexor | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | Terminated | USA | CAN | 0 |